- Home
- CRIS vs LSTA Comparison
CRIS vs LSTA Comparison
Compare CRIS & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- LSTA
- Stock Information
- Founded
- CRIS 2000
- LSTA 1980
- Country
- CRIS United States
- LSTA United States
- Employees
- CRIS N/A
- LSTA N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- LSTA Misc Health and Biotechnology Services
- Sector
- CRIS Health Care
- LSTA Health Care
- Exchange
- CRIS Nasdaq
- LSTA Nasdaq
- Market Cap
- CRIS 32.8M
- LSTA 20.0M
- IPO Year
- CRIS 2000
- LSTA N/A
- Fundamental
- Price
- CRIS $2.84
- LSTA $2.32
- Analyst Decision
- CRIS Strong Buy
- LSTA Strong Buy
- Analyst Count
- CRIS 3
- LSTA 1
- Target Price
- CRIS $23.00
- LSTA $15.00
- AVG Volume (30 Days)
- CRIS 28.2K
- LSTA 17.8K
- Earning Date
- CRIS 05-06-2025
- LSTA 05-08-2025
- Dividend Yield
- CRIS N/A
- LSTA N/A
- EPS Growth
- CRIS N/A
- LSTA N/A
- EPS
- CRIS N/A
- LSTA N/A
- Revenue
- CRIS $10,259,000.00
- LSTA $1,000,000.00
- Revenue This Year
- CRIS N/A
- LSTA N/A
- Revenue Next Year
- CRIS N/A
- LSTA N/A
- P/E Ratio
- CRIS N/A
- LSTA N/A
- Revenue Growth
- CRIS 0.44
- LSTA N/A
- 52 Week Low
- CRIS $2.57
- LSTA $2.05
- 52 Week High
- CRIS $17.49
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- CRIS 41.65
- LSTA 42.12
- Support Level
- CRIS $2.57
- LSTA $2.07
- Resistance Level
- CRIS $3.15
- LSTA $2.62
- Average True Range (ATR)
- CRIS 0.17
- LSTA 0.21
- MACD
- CRIS -0.02
- LSTA 0.01
- Stochastic Oscillator
- CRIS 44.26
- LSTA 47.37
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.